TrialBMC urology2016

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials.

Masahiko Nakayama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.